{"transactions":[{"id":2048536,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-23T21:00:17.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\") was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":1.63,"expiration_date":"2032-06-12","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001213900-23-004539","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000121390023004539/ownership.xml","form_type":"4"}},{"id":2048535,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-23T21:00:17.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\") was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":10.35,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001213900-23-004539","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000121390023004539/ownership.xml","form_type":"4"}},{"id":2048534,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-23T21:00:17.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\") was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-23-004539","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000121390023004539/ownership.xml","form_type":"4"}},{"id":2048533,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-23T21:00:17.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. (\"Ayala\"), Advaxis, Inc. (\"Advaxis\"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the \"Merger Agreement\"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the \"Ayala Common Stock\") was cancelled and converted into the right to receive 0.1874 shares (the \"Exchange Ratio\") of Advaxis common stock (the \"Advaxis Common Stock\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each outstanding option to purchase Ayala Common Stock (each an \"Ayala Option\") was substituted and converted automatically into an option (each, an \"Advaxis Replacement Option\") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.1,"expiration_date":"2028-03-20","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001213900-23-004539","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000121390023004539/ownership.xml","form_type":"4"}},{"id":2048875,"issuer":{"id":93434,"kind":"organization","name":"Ayala Pharmaceuticals, Inc.","symbol":"ADXS"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-01-23T18:18:59.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":1171,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $1.63 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date."}],"balance_after":1171,"derivative":{"exercise_price":8.7,"expiration_date":"2032-06-12","underlying":"Common Stock","underlying_shares":1171},"source":{"system":"sec-edgar","filing":"0001493152-23-002245","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223002245/ownership.xml","form_type":"4"}},{"id":2048874,"issuer":{"id":93434,"kind":"organization","name":"Ayala Pharmaceuticals, Inc.","symbol":"ADXS"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-01-23T18:18:59.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":1171,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $10.35 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable."}],"balance_after":1171,"derivative":{"exercise_price":55.23,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":1171},"source":{"system":"sec-edgar","filing":"0001493152-23-002245","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223002245/ownership.xml","form_type":"4"}},{"id":2048873,"issuer":{"id":93434,"kind":"organization","name":"Ayala Pharmaceuticals, Inc.","symbol":"ADXS"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-01-23T18:18:59.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":2342,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $8.84 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable."}],"balance_after":2342,"derivative":{"exercise_price":47.17,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":2342},"source":{"system":"sec-edgar","filing":"0001493152-23-002245","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223002245/ownership.xml","form_type":"4"}},{"id":2048872,"issuer":{"id":93434,"kind":"organization","name":"Ayala Pharmaceuticals, Inc.","symbol":"ADXS"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-01-23T18:18:59.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":3279,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in the merger of Ayala Pharmaceuticals, Inc. (\"Old Ayala\") into the Issuer (the \"Merger\") in exchange for an employee stock option to acquire 17,500 shares of the common stock of Old Ayala for $5.10 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable."}],"balance_after":3279,"derivative":{"exercise_price":27.21,"expiration_date":"2028-03-20","underlying":"Common Stock","underlying_shares":3279},"source":{"system":"sec-edgar","filing":"0001493152-23-002245","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223002245/ownership.xml","form_type":"4"}},{"id":2231237,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-15T16:15:42.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date."}],"balance_after":6250,"derivative":{"exercise_price":1.63,"expiration_date":"2032-06-12","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0000899243-22-022563","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000089924322022563/doc4.xml","form_type":"4"}},{"id":2669849,"issuer":{"id":108681,"kind":"organization","name":"Old Ayala, Inc","symbol":"ADXS"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-14T17:01:00.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on the earlier of (i) June 10, 2022 or (ii) one day prior to the Company's 2022 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date."}],"balance_after":6250,"derivative":{"exercise_price":10.35,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0000899243-21-023593","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000089924321023593/doc4.xml","form_type":"4"}},{"id":3140556,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-20T18:45:27.000Z","date":"2020-05-18","kind":"exercise","acquired":false,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":3.15,"expiration_date":"2023-09-12","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001209191-20-031023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000120919120031023/doc4.xml","form_type":"4"}},{"id":3140555,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-20T18:45:27.000Z","date":"2020-05-18","kind":"exercise","acquired":true,"shares":28000,"price":3.15,"value":88200.0,"ownership":{"direct":true},"balance_after":36050,"source":{"system":"sec-edgar","filing":"0001209191-20-031023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000120919120031023/doc4.xml","form_type":"4"}},{"id":3491983,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2019-06-13T10:08:46.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":17621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted share units were granted on June 11, 2019 and vest on June 11, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted share units were granted on June 11, 2019 and vest on June 11, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":17621,"derivative":{"underlying":"Ordinary Shares","underlying_shares":17621},"source":{"system":"sec-edgar","filing":"0001209191-19-036584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119036584/doc4.xml","form_type":"4"}},{"id":3511481,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-24T10:11:35.000Z","date":"2019-05-23","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of May 23, 2019."}],"balance_after":7800,"derivative":{"exercise_price":39.44,"expiration_date":"2029-05-23","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001209191-19-032589","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000120919119032589/doc4.xml","form_type":"4"}},{"id":3511480,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-24T10:11:35.000Z","date":"2019-05-23","kind":"grant","acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on May 23, 2020."}],"balance_after":8050,"source":{"system":"sec-edgar","filing":"0001209191-19-032589","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000120919119032589/doc4.xml","form_type":"4"}},{"id":3899690,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-08T20:06:26.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 7, 2018."}],"balance_after":7800,"derivative":{"exercise_price":65.15,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001209191-18-036812","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000120919118036812/doc4.xml","form_type":"4"}},{"id":3899689,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-08T20:06:26.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 7, 2019."}],"balance_after":6300,"source":{"system":"sec-edgar","filing":"0001209191-18-036812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000120919118036812/doc4.xml","form_type":"4"}},{"id":3902679,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2018-06-07T10:49:26.000Z","date":"2018-06-05","kind":"grant","acquired":true,"shares":6041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted share units were granted on June 5, 2018 and vest on June 5, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted share units were granted on June 5, 2018 and vest on June 5, 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":6041,"derivative":{"underlying":"Ordinary Shares","underlying_shares":6041},"source":{"system":"sec-edgar","filing":"0001209191-18-036200","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118036200/doc4.xml","form_type":"4"}},{"id":4286784,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-09T16:07:51.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 8, 2017."}],"balance_after":10000,"derivative":{"exercise_price":52.85,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-038861","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000120919117038861/doc4.xml","form_type":"4"}},{"id":4286783,"issuer":{"id":122210,"kind":"organization","name":"AERIE PHARMACEUTICALS INC","symbol":"AERI"},"owners":[{"id":120544,"kind":"person","name":"GOLDBERG MURRAY A","position":1,"cik":"0001226435","reported_name":"GOLDBERG MURRAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-09T16:07:51.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":1150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 8, 2018."}],"balance_after":4550,"source":{"system":"sec-edgar","filing":"0001209191-17-038861","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1226435/000120919117038861/doc4.xml","form_type":"4"}}]}